TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1606994

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Digoxin 0.5 to 1 mg.d‐1 p.o. for 6 days
Number of subjects: 6
Study: 3891005

Group type: EXPERIMENTAL
Intervention: Latex catheters
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silicone catheters
Number of subjects: 100
Study: 31560372

Group type: EXPERIMENTAL
Intervention: Oral Lefamulin (600 mg every 12 hours for 5 days)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg every 24 hours for 7 days)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Oral Lefamulin
Number of subjects: 738

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 738
Study: 28054374

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 471

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 471
Study: 26481772

Group type: EXPERIMENTAL
Intervention: Video version of the web-based computer-tailored intervention
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Text version of the web-based computer-tailored intervention
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Control condition (not specified in detail)
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: Video version
Number of subjects: 1419
Study: 24238113

Group type: EXPERIMENTAL
Intervention: Stapedoplasty
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Myringoplasty
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Type II tympanoplasty
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Type III tympanoplasty
Number of subjects: 70
Study: 21537360

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment (ICBT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Internet-delivered stress management (ISM)
Number of subjects: 195
Study: 19229451

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and thermal-tactile stimulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thermal-tactile stimulation
Number of subjects: 36
Study: 17346596

Group type: EXPERIMENTAL
Intervention: Transbond XT (light-cured bonding system)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BisCover (polymeric resin polish) applied before bonding with Transbond XT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Blood contamination on acid-etched surfaces
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saliva contamination on acid-etched surfaces
Number of subjects: 120
Study: 14982537

Group type: EXPERIMENTAL
Intervention: Intervention group (curriculum programme with harm minimization goal)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Control group (comparison students)
Number of subjects: 2300
Study: 12520749

Group type: EXPERIMENTAL
Intervention: NP regimen (vinorelbine + cisplatin); vinorelbine: 25 mg/m2 on days 1 and 8, cisplatin: 35 mg/m2 on days 1-3
Number of subjects: 110

Group type: COMPARATOR
Intervention: MVP regimen (mitomycin + vindesine + cisplatin); mitomycin: 6 mg/m2 on day 1, vindesine: 3 mg/m2 on days 1 and 8, cisplatin: 30 mg/m2 on days 1-3
Number of subjects: 110
Study: 9567231

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 20
Study: 7897422

Group type: EXPERIMENTAL
Intervention: 240 mg/day ginkgolide B
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 360 mg/day ginkgolide B
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 2522789

Group type: EXPERIMENTAL
Intervention: Doxacurium 30 micrograms kg‐1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Doxacurium 50 micrograms kg‐1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 27
Study: 355966

Group type: EXPERIMENTAL
Intervention: Betamethasone-17-benzoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30852431

Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psychoeducation (Control)
Number of subjects: 74
Study: 28572066

Group type: EXPERIMENTAL
Intervention: Snack food exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control exposure
Number of subjects: 0
Study: 26446653

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.1%
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.45%
Number of subjects: 91

Group type: COMPARATOR
Intervention: Topical steroid only (Control)
Number of subjects: 91
Study: 22869103

Group type: EXPERIMENTAL
Intervention: Acyclovir (twice-daily)
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3381
Study: 21893708

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-distance technology
Number of subjects: 0
Study: 19838489

Group type: EXPERIMENTAL
Intervention: Green tea (Camellia sinensis) 250 mg capsules
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17309331

Group type: EXPERIMENTAL
Intervention: G17DT (Gastrimmune)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G17DT in combination with gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and gemcitabine
Number of subjects: 0
Study: 15562912

Group type: EXPERIMENTAL
Intervention: Modified surgical technique with acellular dermal matrix graft (ADMG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 32
Study: 11340898

Group type: EXPERIMENTAL
Intervention: Docetaxel therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-drug regimens including docetaxel
Number of subjects: 0
Study: 10036460

Group type: EXPERIMENTAL
Intervention: Nursing practice model based on Aristotelian theory and Rogers' science; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 8161002

Group type: EXPERIMENTAL
Intervention: Atropine (15 micrograms/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (8 micrograms/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Scopolamine (8 micrograms/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30018942

Group type: EXPERIMENTAL
Intervention: Pulsed therapeutic ultrasound (PUS) administered 2 times weekly for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Kneading massage (KM) administered 2 times weekly for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of PUS and KM
Number of subjects: 50
Study: 28827268

Group type: EXPERIMENTAL
Intervention: Running shoe model with 35% difference in cushioning properties (stiffness)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Running shoe model with standard cushioning properties
Number of subjects: 800
Study: 26636511

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) ventilation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Face Mask (FM) ventilation
Number of subjects: 90
Study: 23076403

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham EECP
Number of subjects: 18
Study: 21947297

Group type: EXPERIMENTAL
Intervention: Ad2/HIF‐1α/VP16 (2×10(9) viral particles)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Ad2/HIF‐1α/VP16 (2×10(10) viral particles)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Ad2/HIF‐1α/VP16 (2×10(11) viral particles)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 18426851

Group type: EXPERIMENTAL
Intervention: Intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours
Number of subjects: 116

Group type: COMPARATOR
Intervention: Surfactant only (100 mg/kg of survanta), every 8 hours
Number of subjects: 116
Study: 16490736

Group type: EXPERIMENTAL
Intervention: Surgery + chemotherapy (cisplatin 80 mg/m² on Day 1 and 5-fluorouracil 500 mg/m²/day on Days 1-5)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Surgery-alone
Number of subjects: 89
Study: 14579082

Group type: EXPERIMENTAL
Intervention: Diagnostic strategy based on pretest probability and perfusion lung scan results
Number of subjects: 390
Study: 10858683

Group type: EXPERIMENTAL
Intervention: Modified Alvarado score combined with selective laparoscopy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (other surgical teams)
Number of subjects: 84
Study: 9350066

Group type: EXPERIMENTAL
Intervention: 150 mg pamidronate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 75 mg pamidronate
Number of subjects: 60
Study: 7987528

Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 79

Group type: COMPARATOR
Intervention: Monophasic waveform
Number of subjects: 79
Study: 2722900

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 3 days
Number of subjects: 8
Study: 780041

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Codeine 30 mg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 30351511

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone 1250 mg/day for 3 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oral methylprednisolone 625 mg/day for 3 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 49
Study: 28598202

Group type: EXPERIMENTAL
Intervention: Single oral dose of amlodipine administered in the evening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single oral dose of amlodipine administered in the morning
Number of subjects: 0
Study: 26103668

Group type: EXPERIMENTAL
Intervention: Negative-pressure septal drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anterior nasal packs
Number of subjects: 60
Study: 22645252

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21609410

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 107
Study: 19226203

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1002
Study: 16871477

Group type: EXPERIMENTAL
Intervention: Tizanidine (0.05 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tizanidine (after 6 months monitoring)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40
Study: 15027185

Group type: EXPERIMENTAL
Intervention: BCG-PSN local injection following CO2 laser resection
Number of subjects: 106

Group type: COMPARATOR
Intervention: Interferon subcutaneous injection following CO2 laser resection
Number of subjects: 106
Study: 11576768

Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) 450 mg capsule
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rifampicin‐isoniazid (RIF‐INH) 450+300 mg FDC capsule
Number of subjects: 6
Study: 7551769

Group type: EXPERIMENTAL
Intervention: 8 week training programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maximal exercise testing
Number of subjects: 60
Study: 2030925

Group type: EXPERIMENTAL
Intervention: Large doses of enteric coated (EC) pancreatic enzymes (patient's usual dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Small doses of enteric coated (EC) pancreatic enzymes (1/4 usual dose)
Number of subjects: 9
Study: 7093115

Group type: EXPERIMENTAL
Intervention: Single morning dose of methyldopa
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single evening dose of methyldopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31494596

Group type: EXPERIMENTAL
Intervention: Live‐CCD
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Video‐CCD
Number of subjects: 106

Group type: COMPARATOR
Intervention: Paper‐Cases
Number of subjects: 106
Study: 28035477

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM) used to identify the EBSLN during surgery
Number of subjects: 133

Group type: COMPARATOR
Intervention: No attempt to identify the EBSLN
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 133
Study: 26049549

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system active
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (PLGS system inactive)
Number of subjects: 81
Study: 23618821

Group type: EXPERIMENTAL
Intervention: Targeted Lifestyle Modification Program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 21890134

Group type: EXPERIMENTAL
Intervention: IVF with elective single embryo transfer (IVF‐eSET)
Number of subjects: 116

Group type: COMPARATOR
Intervention: IUI with controlled ovarian stimulation (IUI‐COS)
Number of subjects: 116
Study: 19344622

Group type: EXPERIMENTAL
Intervention: Wet graft
Number of subjects: 384

Group type: COMPARATOR
Intervention: Dry graft
Number of subjects: 384
Study: 16581077

Group type: EXPERIMENTAL
Intervention: Breastfeeding Journal intervention
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 303
Study: 14767255

Group type: EXPERIMENTAL
Intervention: Passive recovery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 12
Study: 11465438

Group type: EXPERIMENTAL
Intervention: PDS foil (0.15 mm)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Titanium dynamic mesh (0.3 mm)
Number of subjects: 28
Study: 9714694

Group type: EXPERIMENTAL
Intervention: PMA-stimulated conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nonstimulated conditions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: RT-PCR analysis
Number of subjects: 15
Study: 10449266

Group type: EXPERIMENTAL
Intervention: Intravaginal 5-fluorouracil (5-FU) cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravaginal placebo cream
Number of subjects: 40
Study: 2468964

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 2,400 mg X 2) + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Number of subjects: 10
Study: 334605

Group type: EXPERIMENTAL
Intervention: Tibicorten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 0
Study: 31794478

Group type: EXPERIMENTAL
Intervention: Tibial cortex transverse distraction
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard surgical treatment (control)
Number of subjects: 136
Study: 31039208

Group type: EXPERIMENTAL
Intervention: Studied further from preferred time of day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subjective sleepiness
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ambient illumination
Number of subjects: 100
Study: 29040598

Group type: EXPERIMENTAL
Intervention: Metformin (up to 1 g twice a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25979364

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lifestyle and medical management
Number of subjects: 120
Study: 23173821

Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter) in patients using corticosteroids at baseline (N=90)
Number of subjects: 248
Study: 22134266

Group type: EXPERIMENTAL
Intervention: Modified cemented prosthesis
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional cemented prosthesis
Number of subjects: 5
Study: 19833477

Group type: EXPERIMENTAL
Intervention: Multiprofessional palliative care team (PCT) fast track
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control care group (best usual care)
Number of subjects: 52
Study: 16902069

Group type: EXPERIMENTAL
Intervention: Hyperoxia (mean end‐tidal O(2) 79.6 +/‐ 2.0%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypoxia (pulse oximeter oxygen saturation 82.6 +/‐ 0.3%)
Number of subjects: 8
Study: 14747646

Group type: EXPERIMENTAL
Intervention: Self-blame condition (N = 31)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control condition (N = 18)
Number of subjects: 49
Study: 11505349

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol, 2mg, given orally twice in 14 hours before the operation
Number of subjects: 21
Study: 9305559

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion at 6.0 +/- 0.4 micrograms.kg-1.min-1 in young adults
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion at 4.3 +/- 0.3 micrograms.kg-1.min-1 in elderly patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion in patients with low plasma cholinesterase activity
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion titrated to maintain 95 +/- 4% twitch depression
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion with or without antagonism
Number of subjects: 51
Study: 8280653

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MAP) 1g/day i.m. 5 days/week for 4 weeks and then 500 mg twice a week
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day orally
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MAP)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 119
Study: 3531560

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 28693969

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity in an aquatic environment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control Group (no specified intervention)
Number of subjects: 140
Study: 27103382

Group type: EXPERIMENTAL
Intervention: Anticoagulant users (n=32)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Baseline anticoagulant use
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Anticoagulant use at any time during the study
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo group (n=624)
Number of subjects: 624
Study: 23931150

Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosal graft urethroplasty
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dorsal inlay buccal mucosal graft urethroplasty
Number of subjects: 47
Study: 21733268

Group type: EXPERIMENTAL
Intervention: Energizer led through-school programme
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1348
Study: 19887824

Group type: EXPERIMENTAL
Intervention: Automated Peritoneal Dialysis (APD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 17351767

Group type: EXPERIMENTAL
Intervention: GABAB receptor agonist baclofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15133591

Group type: EXPERIMENTAL
Intervention: COAST (Croydon Outreach and Assertive Support Team)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 59
Study: 11428734

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler (400 microg, once daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 9543172

Group type: EXPERIMENTAL
Intervention: men1 gene screening in 45 sporadic anterior pituitary tumors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: men1 gene expression analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: loss of heterozygosity (LOH) analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: intragenic polymorphism analysis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: overall conclusion
Number of subjects: 45
Study: 7906757

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (nicoumalone or phenprocoumon)
Number of subjects: 3404

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3404
Study: 2454254

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (weight loss, moderate sodium restriction, reduction of alcohol intake)
Number of subjects: 167
Study: 6179410

Group type: EXPERIMENTAL
Intervention: High-protein supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Balanced protein-calorie supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional treatment
Number of subjects: 0
Study: 31282418

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 14
Study: 27598906

Group type: EXPERIMENTAL
Intervention: Fixed palatal crib
Number of subjects: 41

Group type: COMPARATOR
Intervention: Removable palatal crib
Number of subjects: 41
Study: 25463693

Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device (PCD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study: 24387886

Group type: EXPERIMENTAL
Intervention: HVLA manipulation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study: 22945298

Group type: EXPERIMENTAL
Intervention: rhIGF1 (15 μg/kg per day for 1 month and 30 μg/kg per day for 5 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19294960

Group type: EXPERIMENTAL
Intervention: Auditory stimulation during REM sleep (below-waking threshold tone presentations)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control REM sleep conditions without tone presentations
Number of subjects: 35